Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma

[21] Eads JR(2014)Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance Ann Surg 260 356-363

[22] Allen P(2004)A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 1200-1210

[23] Ko AH(2007)Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 267-277

[24] Engebretson A(2011)Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence Anticancer Res 31 3775-3782

[25] Herman JM(2010)Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer Anticancer Res 30 4819-4828

[26] Strickler JH(2010)Hypxia activates the cyclooxygenase-2-prostaglandin E synthase axis Carcinogenesis 31 427-434

[27] Benson AB(2016)The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells Oncogene 35 2529-2521

[28] Urba S(2015)Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer Cancer Chemother Pharmacol 75 861-867

[29] Yee NS(2011)The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer Lancet Oncol 12 693-702

[30] Kanai Y(2010)LAT1 expression in non-small-cell lung carcinomas: analyses by semiquantitative reverse transcription-PCR (237 cases) and immunohistochemistry (295 cases) Lung Cancer 68 58-65

[21] Eads JR(2014)Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance Ann Surg 260 356-363

[22] Allen P(2004)A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 1200-1210

[23] Ko AH(2007)Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 267-277

[24] Engebretson A(2011)Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence Anticancer Res 31 3775-3782

[25] Herman JM(2010)Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer Anticancer Res 30 4819-4828

[26] Strickler JH(2010)Hypxia activates the cyclooxygenase-2-prostaglandin E synthase axis Carcinogenesis 31 427-434

[27] Benson AB(2016)The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells Oncogene 35 2529-2521

[28] Urba S(2015)Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer Cancer Chemother Pharmacol 75 861-867

[29] Yee NS(2011)The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer Lancet Oncol 12 693-702

[30] Kanai Y(2010)LAT1 expression in non-small-cell lung carcinomas: analyses by semiquantitative reverse transcription-PCR (237 cases) and immunohistochemistry (295 cases) Lung Cancer 68 58-65